Novavax Inc
NASDAQ:NVAX

Watchlist Manager
Novavax Inc Logo
Novavax Inc
NASDAQ:NVAX
Watchlist
Price: 8.91 USD -4.4%
Market Cap: 1.4B USD
Have any thoughts about
Novavax Inc?
Write Note

P/E
Price to Earnings

-5.2
Current
-1.6
Median
22.7
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-5.2
=
Market Cap
1.4B USD
/
Net Income
-284.9m USD
All Countries
Close
Market Cap P/E
US
Novavax Inc
NASDAQ:NVAX
1.4B USD -5.2
FR
Pharnext SCA
OTC:PNEXF
6T USD -180 532.6
US
Abbvie Inc
NYSE:ABBV
314.3B USD 61.9
US
Amgen Inc
NASDAQ:AMGN
142.4B USD 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD -248.1
US
Gilead Sciences Inc
NASDAQ:GILD
112.1B USD 888
US
Epizyme Inc
F:EPE
94.1B EUR -473.3
AU
CSL Ltd
ASX:CSL
135.4B AUD 33.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.3B USD 17.6
US
Seagen Inc
F:SGT
39.3B EUR -54.8
NL
argenx SE
XBRU:ARGX
34.5B EUR -129.4
Earnings Growth
US
Novavax Inc
NASDAQ:NVAX
Average P/E: 206.8
Negative Multiple: -5.2
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 532.6 N/A
US
Abbvie Inc
NYSE:ABBV
61.9
412%
US
Amgen Inc
NASDAQ:AMGN
33.1
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -248.1
42%
US
Gilead Sciences Inc
NASDAQ:GILD
888
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -473.3 N/A
AU
CSL Ltd
ASX:CSL
33.3
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.6
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.8 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.4 N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-10.9
2-Years Forward
P/E
-53.8
3-Years Forward
P/E
9.9

See Also

Discover More